Answers are grounded in this paper and cite their sources.
The insulin-like growth factors, IGF-I and IGF-II, circulate in serum either in a free state, bound to one of six high affinity IGF binding proteins (IGFBP-1 to IGFBP-6), or in growth hormone (GH) dependent ternary complexes with IGFBP-3 or IGFBP-5 and the acid-labile subunit (ALS). Unresolved issues include to what extent circulating IGF levels reflect tissue bioavailable IGFs, the role of serum IGFBP-3 proteolysis in IGF bioavailability and whether measurement of “free IGF” has an advantage over total serum IGF. Total serum IGF-I levels may be related to the presence of an IGF-I gene polymorphism. A concept is emerging that total serum IGF-I levels in the healthy population may reflect long-term tissue IGF bioactivity. Whereas serum IGF-I is associated with maintenance of bone density, chronically high-normal total serum IGF-I levels may be a risk factor for the development of some common malignancies. This review will address recent reports that provide insight into serum IGF kinetics and bioavailability.
No takes yet. Share an insight, caveat, or question.
Twigg et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: